CN Patent

CN112451518B — 生育三烯酚的经粘膜递送

Assigned to Vicket Biological Technology Co ltd · Expires 2025-02-21 · 1y expired

What this patent protects

本发明涉及配制用于经粘膜递送并且特别是舌下递送的药物组合物,这些药物组合物包括至少一种生育三烯酚或其衍生物,连同一种或多种药学上可接受的赋形剂。本发明进一步涉及所述组合物用于治疗或预防运动后肌肉酸痛、延迟性肌肉酸痛、心肌纤维化、高血压、炎症、中风、癌症、高胆固醇和/或甘油三酯、脱发、肥厚、由辐射照射引起的病症、稳定和/或控制血糖水平、以及改善运动耐力和能力的用途。

USPTO Abstract

本发明涉及配制用于经粘膜递送并且特别是舌下递送的药物组合物,这些药物组合物包括至少一种生育三烯酚或其衍生物,连同一种或多种药学上可接受的赋形剂。本发明进一步涉及所述组合物用于治疗或预防运动后肌肉酸痛、延迟性肌肉酸痛、心肌纤维化、高血压、炎症、中风、癌症、高胆固醇和/或甘油三酯、脱发、肥厚、由辐射照射引起的病症、稳定和/或控制血糖水平、以及改善运动耐力和能力的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN112451518B
Jurisdiction
CN
Classification
Expires
2025-02-21
Drug substance claim
No
Drug product claim
No
Assignee
Vicket Biological Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.